Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
10.1007/s13770-022-00515-8
- Author:
Seungyong SHIN
1
;
Pyunghwajun LEE
;
Jieun HAN
;
Se-Na KIM
;
Jaesung LIM
;
Dae-Hwan PARK
;
Taejong PAIK
;
Junhong MIN
;
Chun Gwon PARK
;
Wooram PARK
Author Information
1. Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi 16419, Republic of Korea
- Publication Type:REVIEW ARTICLE
- From:
Tissue Engineering and Regenerative Medicine
2023;20(3):371-387
- CountryRepublic of Korea
- Language:English
-
Abstract:
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) has emerged as an innovative immunotherapy for hematological cancer treatment. However, the limited effect on solid tumors, complex processes, and excessive manufacturing costs remain as limitations of CAR-T therapy. Nanotechnology provides an alternative to the conventional CAR-T therapy. Owing to their unique physicochemical properties, nanoparticles can not only serve as a delivery platform for drugs but also target specific cells. Nanoparticle-based CAR therapy can be applied not only to T cells but also to CAR-natural killer and CAR-macrophage, compensating for some of their limitations. This review focuses on the introduction of nanoparticle-based advanced CAR immune cell therapy and future perspectives on immune cell reprogramming.
